‘Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART’ authored by Ying Zhao, Jacqueline Voget, Isaac Singini, Zaayid Omar, Vanessa Mudaly, Andrew Boulle, Gary Maartens and Graeme Meintjes is on its way. Stay tuned for thought-provoking insights and valuable information coming your way 26 April 2024! Contribution excerpt: ‘This study supports switching to TLD as a third-line regimen or an alternative second-line regimen after PI regimen failure in a programmatic setting, with the caveat that patients switched to TLD in our study had no tenofovir resistance.'